Home/Filings/4/0001415889-25-023209
4//SEC Filing

Cline Christopher R. 4

Accession 0001415889-25-023209

CIK 0001438533other

Filed

Aug 27, 8:00 PM ET

Accepted

Aug 28, 4:05 PM ET

Size

5.3 KB

Accession

0001415889-25-023209

Insider Transaction Report

Form 4
Period: 2025-08-27
Cline Christopher R.
CHIEF FINANCIAL OFFICER
Transactions
  • Sale

    Common Stock

    2025-08-27$17.31/sh470$8,13692,656 total
Footnotes (1)
  • [F1]This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of additional shares to cover the tax obligation that occurred upon the vesting of performance-based restricted stock units (PSUs) that vested in May 2025.

Issuer

Travere Therapeutics, Inc.

CIK 0001438533

Entity typeother

Related Parties

1
  • filerCIK 0001943192

Filing Metadata

Form type
4
Filed
Aug 27, 8:00 PM ET
Accepted
Aug 28, 4:05 PM ET
Size
5.3 KB